Clinical Trials
1
Active:0
Completed:0
Trial Phases
1 Phases
Phase 2:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (1 trials with phase data)• Click on a phase to view related trials
Phase 2
1 (100.0%)Y- Shaped Pegylated Interferon (YPEG-IFNα-2a) Plus Ribavirin in Egyptian Patients With Untreated Chronic Hepatitis C
Phase 2
- Conditions
- Self EfficacyHepatitis C
- Interventions
- Drug: pegylated interferon alpha 2a YPEG-IFN α-2a 180mcg
- First Posted Date
- 2011-04-04
- Last Posted Date
- 2011-04-04
- Lead Sponsor
- BioGeneric Pharma
- Target Recruit Count
- 300
- Registration Number
- NCT01327729
- Locations
- 🇪🇬
Kasr Alaini school of medicne, Cairo, Egypt
News
No news found